The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study

Autor: Sozeri, Betul, Ulu, Kadir, Kaya-Akça, Ummusen, Haslak, Fatih, Pac-Kisaarslan, Aysenur, Otar-Yener, Gulcin, Baba, Ozge, Altug-Gucenmez, Ozge, Sahin, Nihal, Bağlan, Esra, Sönmez, Hafize Emine, Cakmak, Figen, Ozturk, Kubra, Gezgin-Yıldırım, Deniz, Şener, Seher, Barut, Kenan, Batu, Ezgi Deniz, Yıldız, Mehmet, Basaran, Ozge, Adrovic, Amra, Sahin, Sezgin, Ozdel, Semanur, Bilginer, Yelda, Poyrazoglu, Muammer Hakan, Demir, Ferhat, Yuksel, Selcuk, Kalyoncu, Mukaddes, Kasapcopur, Ozgur, Ozen, Seza, Aktay-Ayaz, Nuray
Rok vydání: 2021
Předmět:
Male
polymerase chain reaction
retrospective study
Observational Research
Pediatrics
Etanercept
computer assisted tomography
chemistry.chemical_compound
rituximab
adalimumab
Severe acute respiratory syndrome coronavirus 2
Immunology and Allergy
Child
connective tissue
azithromycin
tofacitinib
Biologic drugs
disease course
artificial ventilation
hospital patient
biological therapy
Antirheumatic Agents
Disease Progression
Female
biological product
pediatric patient
anakinra
hospitalization
medicine.drug
medicine.medical_specialty
abatacept
Adolescent
prevalence
Immunology
complication
canakinumab
Article
tocilizumab
coronavirus disease 2019
Tocilizumab
Rheumatology
Rheumatic Diseases
Internal medicine
medicine
Adalimumab
Humans
human
Retrospective Studies
Biological Products
Anakinra
business.industry
Abatacept
COVID-19
major clinical study
Infliximab
enzyme linked immunosorbent assay
Canakinumab
multicenter study
chemistry
antirheumatic agent
disease exacerbation
Rheumatic disease
business
disease activity
Zdroj: Rheumatology International
ISSN: 1437-160X
0172-8172
DOI: 10.1007/s00296-021-05008-w
Popis: The effects of biological disease-modifying antirheumatic drugs (bDMARDs) in the clinical course of COVID-19 on children with underlying rheumatologic diseases have not been fully demonstrated. To evaluate the course of COVID-19 infection in patients with rheumatic disease receiving bDMARD treatment. This was a retrospective, multicenter study conducted in pediatric patients infected by SARS-CoV-2 and under bDMARDs therapy. The study population consisted of 113 patients (72 female/41 male). The mean age of the patients was 12.87 ± 4.69 years. The primary diagnosis of the cohort was as follows: 63 juvenile idiopathic arthritis, 35 systemic autoinflammatory diseases, 10 vasculitides, and five cases of connective tissue diseases. The mean duration of the primary disease was 4.62 ± 3.65 years. A total of 19 patients had additional comorbid diseases. Thirty-five patients were treated with canakinumab, 25 with adalimumab, 18 with etanercept, 10 with infliximab, nine with tocilizumab, six with rituximab, four with anakinra, three with tofacitinib, and one with abatacept. The median exposure time of the biological drug was 13.5 months. Seventy-one patients had symptomatic COVID-19, while 42 were asymptomatic. Twenty-four patients required hospitalization. Five patients presented with MIS-C. The hospitalized patients were younger and had a shorter duration of rheumatic disease compared to ambulatory patients, although the difference was not statistically significant. Steroid usage, presence of fever, and dyspnea were more common among the hospitalized patients. A worsening in the course of both COVID-19 and current disease was not noticed under bDMARDs, however, to end with a strong conclusion multicentric international studies are required. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Databáze: OpenAIRE
Externí odkaz: